Teverelix

Summary

Teverelix is an investigational gonadotropin‑releasing hormone (GnRH) antagonist being evaluated for androgen‑deprivation therapy in hormone‑sensitive advanced prostate cancer. Administered as an injectable peptide, it aims to rapidly suppress luteinizing hormone (LH), follicle‑stimulating hormone (FSH) and downstream testosterone production.

Mechanism of Action

Teverelix is a decapeptide that competitively and reversibly binds to GnRH receptors on pituitary gonadotrophs. This blocks the normal GnRH signal, leading to an immediate fall in LH and FSH secretion. The reduced LH diminishes Leydig‑cell stimulation, rapidly lowering testosterone synthesis in men (and estradiol in women). The antagonistic action avoids the initial hormonal flare seen with GnRH agonists and produces a reversible, dose‑dependent suppression of gonadal steroids.

What the Research Shows

Early human studies demonstrated dose‑dependent suppression of LH, FSH and testosterone after single subcutaneous doses of 0.5‑5 mg, with testosterone falling below 1 ng/mL within 12 hours and lasting up to 33 hours at the highest dose. Pharmacokinetic data showed rapid absorption (tmax 1‑4 h) and a terminal half‑life of 24‑75 h, with dose‑proportional exposure up to 120 mg. Phase 2 loading‑dose trials in men with advanced prostate cancer compared several subcutaneous and intramuscular regimens. Two subcutaneous regimens (90 mg and 180 mg over three days) achieved median castration for 55‑69 days, with >90 % of patients below 0.5 ng/mL testosterone at day 28. A later multicenter phase 2 study using combined SC + IM loading (120 + 120 mg or 180 + 180 mg) followed by six‑weekly SC maintenance showed a 97.5 % castration rate at day 28 for the higher‑dose group, though levels fell by day 42. Across studies, injection‑site reactions were the most frequent adverse events, generally mild, and no severe safety signals emerged.

Reported Benefits

Evidence from early‑phase trials indicates that teverelix can achieve rapid testosterone suppression (within 1‑2 days) and high short‑term castration rates, especially with higher loading doses. The antagonist format avoids the testosterone surge seen with GnRH agonists and may provide a convenient injectable regimen with both subcutaneous and intramuscular options.

Limitations of the Evidence

Data are limited to uncontrolled phase 1 and phase 2 studies with modest sample sizes; long‑term efficacy and durability of castration have not been demonstrated. Comparative effectiveness versus approved GnRH antagonists (e.g., degarelix) is lacking, and the optimal maintenance dosing schedule remains unsettled. Safety information is confined to short‑term observation, primarily injection‑site irritation.

Safety Considerations

The most commonly reported adverse events are mild injection‑site reactions (induration, erythema) and hot flushes. No severe or life‑threatening adverse events were recorded in the published trials. Because the drug suppresses sex steroids, clinicians should monitor for typical hormone‑deprivation effects (e.g., bone density loss, metabolic changes) and counsel patients accordingly.

How It Is Administered

Teverelix is supplied as an injectable formulation for subcutaneous or intramuscular administration. Loading regimens have involved single or multiple injections over 2‑3 days, with doses ranging from 90 mg to 180 mg per route. Maintenance dosing in later studies used subcutaneous injections every six weeks. Formulation specifics (e.g., acetate vs trifluoroacetate salt) differ between studies but are all delivered by injection.

Routes of Administration

Goals & Uses

• Treatment of endometriosisGynecologyLow
• Prevention of premature LH surge in assisted reproductionReproductive MedicineLow
• Testosterone suppression in prostate cancerOncologyModerate
• Reduction of lower urinary tract symptoms in BPHUrologyModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Known hypersensitivity to GnRH antagonists or any peptide excipientAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• Injection site reactionsLocalCommon
• Anaphylaxis / hypersensitivityImmunologicRare
• Decreased libidoSexual / EndocrineCommon
• Erectile dysfunctionSexual/ReproductiveCommon
• Hot flushesVasomotorCommon
• Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

• Antidiabetic agentsLow
• QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)Moderate

Population Constraints

• Pediatric patientsAgeAbsolute
• Patients with pre-existing osteoporosisMusculoskeletalRelative
• Patients with cardiovascular diseaseComorbidityRelative
• Women of childbearing potentialReproductiveRelative

Regulatory Status

• European UnionInvestigationalInvestigated under EMA oversight in clinical trials; no marketing authorization granted. Ardana Bioscience (Edinburgh, UK) conducted European trials.
• United StatesInvestigationalTeverelix was studied in clinical trials but never received FDA approval. Development was discontinued.
• United KingdomInvestigationalNo MHRA approval; studied in UK-based clinical programs prior to Ardana's dissolution.

Teverelix has not received regulatory approval from the FDA, EMA, or other major agencies. Clinical development was pursued by Ardana Bioscience and later other entities; development was halted or suspended. No approved indication exists in any major jurisdiction.

Evidence & Sources

• Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies
  Journal ArticleModerateMacLean CM, et al.2023-01-01T00:00:00.000000Z
• Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study
  Journal ArticleModerateErb K, et al.2000-01-01T00:00:00.000000Z
• Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult Subjects
  Journal ArticleModerateMacLean CM, et al.2022-01-01T00:00:00.000000Z
• GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
  Journal ArticleModeratePatel S, et al.2024-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleModerateBayes M, Rabasseda X, Prous JR2006-01-01T00:00:00.000000Z
• Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial
  Journal ArticleModerateUlys A, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions